Condition

HIV Seropositivity

ClinicalTrials.gov condition label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 65 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials65

Recruiting2

Common interventions25

Lead sponsors shown15

Clinical trials

60 shown

Immuno-virological Evaluation of Persons Living With HIV (PLWH)NCT05973825 · 2025-02-13

Hybrid Type I Effectiveness-Implementation Trial of a Social Network Support InterventionNCT05723653 · 2023-02-13

Study of the Prevalence of Transmitted HIV-1 Resistance, Viral Diversity, and Cluster Identification in Patients at the Time of HIV-1 DiagnosisNCT07146529 · 2025-09-01

NOT_YET_RECRUITING

Clinical Trial of Gammora® Plus Antiretroviral Treatment for HIVNCT06799650 · 2025-01-01

ACTIVE_NOT_RECRUITING

A Multilevel, Multiphase Optimization Strategy for PrEP (MOST:PrEP)NCT06334341 · 2024-06-19

ENROLLING_BY_INVITATION

Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIVNCT05122026 · 2024-01-17

ACTIVE_NOT_RECRUITING

The Evaluation of Anti-interference Ability and Clinical Specificity of HIV Ag +Ab Assay Kit (Sysmex)NCT05983536 · 2023-09-20

Lower Urinary Tract Symptoms in Males Living With HIVNCT05964803 · 2023-08-01

Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis PatientsNCT05118490 · 2023-07-19

ACTIVE_NOT_RECRUITING

The Value of HPV Testing for Cervical Cancer Screening in Women Living With HIV (PAPILLO-VIH)NCT05968183 · 2023-07-01

Telehealth Delivery (Tele-B6)NCT05829759 · 2023-04-18

A Pilot Study of Metformin to Reduce Cerebrovascular Dysfunction in Participants With HIV and Metabolic Syndrome.NCT05571319 · 2022-08-11

Collision of Three Global Pandemics: the Effect of Tuberculosis and HIV on the Epidemiological, Clinical, Virological and Immunological Trajectory of COVID-19 in Botswana and NamibiaNCT05268380 · 2022-08-01

Expectation, Motivation and Experience of HIV-patients Regarding Participation to an HIV Cure-related Clinical TrialNCT05280392 · 2022-06-21

Effects of Cannabidiol (CBD) on the Activation of Autophagy and Inflammation Genes, Functional Consequences in Virologically Controlled HIV-infected PatientsNCT05306249 · 2022-05-16

Implementation of STTR Strategies Among People Who Inject Drugs in MalaysiaNCT03987282 · 2022-04-26

Precariousness and Sexual Vulnerability of People From Haiti Living With or Without HIV in French GuianaNCT05174234 · 2021-11-04

Assessing the PrEP Care Cascade Among Black Men and Transwomen in the Southeastern USNCT04832477 · 2021-09-15

Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone ClinicsNCT04706624 · 2021-06-29

Evaluation of Post-SARS-CoV-2 Vaccinal Response in Immunocompromised PatientsNCT05672654 · 2021-05-10

Evaluation of Secondary Distribution of HIV Self-screening Tests by Women With HIVNCT05074251 · 2021-04-20

DIAGNOSIS of PULMONARY TUBERCULOSIS Through HUMAN BREATH (TBENOSE)NCT04682990 · 2021-01-05

National Survey About Trajectory and Life Conditions of HIV Trans People in FranceNCT04849767 · 2020-10-01

Investigation of the Psychosocial Factors Responsible for the Late Recourse to HIV Testing Within MSMNCT03661203 · 2020-09-01

iTransition DevelopmentNCT04383223 · 2020-08-28

Supporting Health Behavior Among Persons Living With HIV Using Tech, MOST, and Behavioral EconomicsNCT04518241 · 2020-08-14

Early Community Client-LED ART Delivery in Nakivale Refugee SettlementNCT04736316 · 2020-06-29

Interaction Between HIV and PlateletsNCT04062825 · 2020-04-17

Initiation of First-line Antiretroviral Treatment With TENOFOVIR ALAFENAMIDE - EMTRICITABINE - BICTEGRAVIR at the First Clinical Contact in France: Trial IMEA 055 - FASTNCT03858478 · 2019-11-18

Seroincidence Study Among Men Who Have Sex With Men and Transgender Women - The ImPrEP Seroincidence StudyNCT05674682 · 2019-10-01

HIV and HCV Infections in 2 Communes From the Battambang Province, Cambodia: Prevalence Rates, Viral Strains, and Unsafe Injection Practices (12352 ANRS ROK INVEST)NCT04044586 · 2019-09-01

Free HIV Testing in Private Biological Laboratories: A New Offer to Encourage HIV TestingNCT04030689 · 2019-07-01

ANRS12373 GUNDO SO - Evaluation of an Empowerment Program for WLHIV in MaliNCT03795415 · 2019-05-27

Sport and Self Esteem in Patients Living With HIVNCT03920969 · 2019-02-01

Proviral DNA as a Target for HIV-1 Resistance AnalysisNCT04088916 · 2018-10-15

Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current RegimenNCT03333083 · 2018-05-03

Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAMNCT03311945 · 2018-05-02

Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to RaltegravirNCT03374358 · 2018-01-10

Improving Clinic Attendance for Medication Collection Among HIV Positive Individuals in NepalNCT03367130 · 2017-10-14

Regional Differences in Human Immunodeficiency Virus (HIV) TestingNCT03158987 · 2017-06-01

Relationship Between Neuromuscular Fatigue, Perceived Tiredness and Level Of Physical Activity of Patients Living With HIVNCT03124914 · 2017-04-19

Community-based Distribution of Oral HIV Self-testing KitsNCT02994329 · 2017-01-18

Telephone Counseling to Enhance the Quality and Safety of Romantic and Sexual Relationships in People Living and Aging With HIVNCT03004170 · 2016-12-01

Effects of E-cigarettes (ECIGs) on Pulmonary Inflammation and Behavior in HIV Infected SmokersNCT02848586 · 2016-08-01

Monitored Antiretroviral Pause in Chronic HIV-Infected Subjects With Long-Lasting Suppressed ViremiaNCT03198325 · 2016-07-27

COPANA - A09 PCSK 9 Substudy: Impact of Protease Inhibitors on PCSK9 Levels in Naive HIV-Infected PatientsNCT03139630 · 2016-03-01

Safer Conception Intervention for HIV-1 Serodiscordant CouplesNCT03030768 · 2016-02-01

Evaluation of the PrePex Device for Rapid Scale-up of VMMC, Phase 3 Field Implementation Trial With HIV + Adult MalesNCT03218839 · 2015-10-01

Effects of VSL#3 on Neuro-cognitive Profile of HIV PatientsNCT02276326 · 2014-07-01

Anti-HIV False Positivity Rate in Pregnant Women; and Investigating the Factors Affecting This SituationNCT03777371 · 2014-01-01

Assessment of Age-related Hearing Loss in HIV-1 PatientsNCT02154971 · 2013-11-18

Prevalence of Cerebral Small Vessel Disease in HIV Infected PatientsNCT02082574 · 2013-07-01

Statins for Pulmonary and Cardiac Complications of Chronic HIV - Coordinating CenterNCT01881971 · 2013-05-01

Fluoride Metabolism, Bone Remodelling and Mineral Density in HIV Patients Treated With Tenofovir +/- EmtricitabineNCT01813292 · 2013-05-01

Revealing Increased Axonal Loss in Treated HIV PatientsNCT02003989 · 2013-05-01

An Evaluation of a Rapid Test for HIVNCT01733927 · 2010-05-01

Lovastatin: Immunomodulatory Value EvaluationNCT00721305 · 2008-08-01

Effectiveness Study Low-Dose Naltrexone Versus ARV's for HIV+NCT01174914 · 2008-03-01

Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency VirusNCT00797030 · 2006-10-01

A Pilot Study to Investigate the Safety and Immunologic Activity AGS-004 an Autologous HIV Immunotherapeutic Agent.NCT00381212 · 2006-09-01

Common interventions

RaltegravirDRUG3 LamivudineDRUG2 PlaceboDRUG2 poly I-poly C12UDRUG2 AGS-004BIOLOGICAL1 Anti HIV Seropositive Pregnant WomenOTHER1 ARV's + PlaceboOTHER1 Best Practice AlertBEHAVIORAL1 Biktarvy armDRUG1 Blood drawDIAGNOSTIC_TEST1 Case management and referred substance abuse treatmentBEHAVIORAL1 CBD LGP 50DRUG1 Chest X-RayOTHER1 Clinic-based substance abuse treatment with buprenorphineBEHAVIORAL1 Computer-based simulation training for providersBEHAVIORAL1 Contingency management (12 weeks)BEHAVIORAL1 Contingency management (6 weeks)BEHAVIORAL1 Counseling and referral for partner testingBEHAVIORAL1 Counseling on timed condomless sex, ART and PrEP adherenceBEHAVIORAL1 Covid-19, TB and HIV diagnosisDIAGNOSTIC_TEST1 CT Scan with SpirometryDEVICE1 cyclosporine and sodium carboximethycelluloseDRUG1 Daily rifapentine and isoniazid for 4 weeksDRUG1 data collected from patient fileOTHER1 Delayed intervention (waitlist control)BEHAVIORAL1

Mapped drugs appearing in these trials

Shared trial participation only; not evidence of efficacy or approval.

raltegravir3 lamivudine2 placebo2 isoniazid1 lovastatin1 metformin Extended Release Oral Tablet1 naltrexone1 rifapentine1

Leading sponsors

ANRS, Emerging Infectious Diseases 5 Fondation Ophtalmologique Adolphe de Rothschild 3 University of Washington 3 AIM ImmunoTech Inc. 2 Centre Hospitalier Universitaire de Nice 2 Emory University 2 Judit Pich 2 The Aurum Institute NPC 2 University Hospital, Ghent 2 Alison Morris 1 Assistance Publique - Hôpitaux de Paris 1 Azienda Policlinico Umberto I 1 Centre Hospitalier de Cayenne 1 Centre Hospitalier de Saint-Denis 1 Centre Hospitalier le Mans 1

Trial status mix

COMPLETED41

UNKNOWN11

TERMINATED5

ACTIVE_NOT_RECRUITING3

RECRUITING2

ENROLLING_BY_INVITATION1

NOT_YET_RECRUITING1

WITHDRAWN1

Phase mix

NA22

PHASE210

PHASE44

PHASE33

PHASE12

EARLY_PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.